Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 10Plavix
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 1,454
2018 Revenue in Millions : 1,570
Growth (%) : -7
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,108
2019 Revenue in Millions : 1,614
Growth (%) : -31
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,023
2020 Revenue in Millions : 998
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,078
2021 Revenue in Millions : 1,023
Growth (%) : 5
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,023
2022 Revenue in Millions : 1,078
Growth (%) : -4
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : 0.30%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 2,048
2014 Revenue in Millions : 2,122
Growth (%) : 4%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 1,637
2015 Revenue in Millions : 2,045
Growth (%) : -20
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 1,824
2016 Revenue in Millions : 1,915
Growth (%) : -5
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 1,627
2017 Revenue in Millions : 1,662
Growth (%) : -2%